Crossmark

The translational journey of cancer nanomedicines: biological and entrepreneurial lessons learned

Published Online: 2025-04-30

Published Print: 2025-10

Authors

Rijcken, Cristianne Johanna Ferdinand https://orcid.org/0009-0006-8490-1376
License Information

Text and Data Mining valid from 2025-04-30

Version of Record valid from 2025-04-30
More Information

Article History

Accepted: 18 April 2025

First Online: 30 April 2025

Declarations

:

: Not relevant.

: CR.

: CR is shareholder of Cristal Therapeutics and Liberates.

Document is current